Appendix Table C7. KQ1 Outcome I. Hematologic response: Epoetin versus control

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study author** | **Hb response definition** | **Epo n** | **Epo N** | **Proportion (%)** | **Control n** | **Control N** | **Proportion (%)** | **Comments** |
| **Hb at baseline < 10 g/dL** |  |  |  |  |  |  |  |  |
| **Boogaerts 2003** | Hb increase of 2 g/dL during the treatment phase without transfusion requirements after the initial 4 treatment wks | 63 | 133 | 47.37% | 17 | 129 | 13.18% | data were included in Cochrane Review 2004 as Coiffier 2001 |
| **Case 1993** | Hct increase of 6% from baseline independent of transfusion | 46 | 79 | 58.23% | 10 | 74 | 13.51% | Hct definition |
| **Dammacco 2001** | Hb increase of 2 g/dL independent of transfusion | 38 | 66 | 57.58% | 6 | 66 | 9.09% |  |
| **Henry 1995** | Hct increase of 6% from baseline independent of transfusion | 31 | 64 | 48.44% | 4 | 61 | 6.56% | Hct definition |
| **Littlewood 2001** | Hb increase of 2 g/dL independent of transfusion in the previous 28 days | 172 | 244 | 70.49% | 22 | 115 | 19.13% | efficacy population: patients on study at least 28 days |
| *Oberhoff 1998* | Hb increase of 2 g/dL independent of transfusion | 38 | 114 | 33.33% | 7 | 104 | 6.73% | at week 12, data submitted for Cochrane Review |
| **Osterborg 2002** | Hb increase of 2 g/dL independent of transfusion within 6 wks | 114 | 170 | 67.06% | 46 | 173 | 26.59% | at end of week 16 |
| **Razzouk 2006** | Hb increase at any time after 4 wks independent of red blood cell transfusions | 63 | 111 | 56.76% | 39 | 111 | 35.14% |  |
| *Rose 1994* | Hb Hct increase of > 6% of Hct unrelated to transfusion | 67 | 142 | 47.18% | 13 | 79 | 16.46% | Hct definitions, data submitted for Cochrane Review |
| **Witzig 2004** | Hb increase of 2 g/dL from baseline | 120 | 165 | 72.73% | 52 | 164 | 31.71% | unclear if independent of transfusion |

Appendix Table C7. KQ1 Outcome I. Hematologic response: Evidence table Epoetin versus Control (continued)

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study author** | **Hb response definition** | **Epo n** | **Epo N** | **Proportion (%)** | **Control n** | **Control N** | **Proportion (%)** | **Comments** |
| **Hb at baseline 10 to 12 g/dL** |  |  |  |  |  |  |  |  |
| **Aapro 2008** | Hb increase of 2 g/dL from baseline without transfusions in the previous 6 wks | 157 | 231 | 67.97% | 32 | 232 | 13.79% |  |
| **Bamias 2003** | Hb increase of 2 g/dl | 15 | 72 | 20.83% | 2 | 72 | 2.78% | unclear if independent of transfusion |
| **Chang 2005** | Hb increase of 2 g/dl independent of transfusion in the previous 28 days | 115 | 175 | 65.71% | 11 | 175 | 6.29% | Hb response was evaluated retrospectively |
| **Iconomou 2003** | Hb increase of 2 g/dl | 25 | 57 | 43.86% | 7 | 55 | 12.73% | after 12 wks of treatment, unclear if independent of transfusion |
| **Milroy 2011** | Hb increase of ≥ 2/dL from baseline or partial response with inc of 1-1.99 g/dL | 71 | 189 | 37.6% | 17 | 191 | 8.9% |  |
| **Savonije 2005** | Hb increase of 2 g/dl independent of transfusion in the previous 28 days | 143 | 208 | 68.75% | 31 | 100 | 31.00% |  |
| **Hb at baseline not reported** | | | | | | | | |
| ML17620 | Hb increase of 2 g/dL without transfusions in the previous 6 wks | 29 | 61 | 47.54% | 14 | 60 | 23.33% |  |